Form 10-K

Overview

The report states that Lexaria granted six new patents in fiscal 2025, including firsts in Australia, Japan, and its diabetes family. It describes completed human pilot studies, an animal study, and an Australian chronic clinical trial focused on GLP-1/GIP and CBD formulations. Consolidated revenue increased to $705,923, while the company reported seven full-time salaried employees and continuing substantial doubt about its ability to continue as a going concern.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 August 2025
Publication date: 26 November 2025
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services